Literature DB >> 20965791

Discontinuation of diabetes and lipid-lowering medications after bariatric surgery at Veterans Affairs medical centers.

Matthew L Maciejewski1, Edward H Livingston, Leila C Kahwati, William G Henderson, Andrew L Kavee, David E Arterburn.   

Abstract

BACKGROUND: Bariatric surgery has largely been performed on middle-age female populations and been associated with significant medication discontinuation; however, it is unknown whether similar medication discontinuation rates could be achieved in men. The purpose of the present analysis was to examine the discontinuation rate of diabetes or lipid-lowering medications and the patient factors associated with medication discontinuation among veterans undergoing bariatric surgery.
METHODS: We identified the demographic and health status information for 284 veterans with diabetes and 298 veterans with hyperlipidemia who had undergone bariatric surgery at 1 of 12 Veterans Affairs bariatric centers in 2000 to 2006 from the Veterans Affairs National Surgical Quality Improvement Program data. We also identified the medications that had been prescribed and discontinued using the Veterans Affairs administrative data. Medication discontinuation was estimated using a logistic regression model.
RESULTS: Of the 284 veterans with diabetes and 298 with hyperlipidemia, 52% and 40% had discontinued their medications at 1 year, respectively. The veterans with diabetes were more likely to discontinue medication if they had been taking oral hypoglycemic agents alone (odds ratio 2.77, P <.001) than were those taking insulin or oral hypoglycemic agents and insulin. The veterans with hyperlipidemia were more likely to discontinue medication if they had only been taking fibrates (odds ratio 6.15, P <.01) than were those veterans taking statins and fibrates.
CONCLUSION: Bariatric surgery led to significant medication discontinuation within 1 year for high-risk veterans with diabetes or hyperlipidemia.
Copyright © 2010 American Society for Metabolic and Bariatric Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20965791     DOI: 10.1016/j.soard.2010.07.005

Source DB:  PubMed          Journal:  Surg Obes Relat Dis        ISSN: 1550-7289            Impact factor:   4.734


  5 in total

Review 1.  Influence of bariatric surgery on the use and pharmacokinetics of some major drug classes.

Authors:  Jan Peter Yska; Susanne van der Linde; Véronique V Tapper; Jan A Apers; Marloes Emous; Erik R Totté; Bob Wilffert; Eric N van Roon
Journal:  Obes Surg       Date:  2013-06       Impact factor: 4.129

Review 2.  Clinical Outcomes of Metabolic Surgery: Microvascular and Macrovascular Complications.

Authors:  Ted D Adams; David E Arterburn; David M Nathan; Robert H Eckel
Journal:  Diabetes Care       Date:  2016-06       Impact factor: 19.112

Review 3.  Can Bariatric Surgery be Considered Standard Therapy to Treat Type 2 Diabetes?

Authors:  Karen Meyvis; Christophe De Block; Luc F Van Gaal
Journal:  Eur Endocrinol       Date:  2013-08-23

4.  Influence of bariatric surgery on the use of medication.

Authors:  Jan Peter Yska; Douwe H van der Meer; Albert R Dreijer; Willeke Eilander; Jan A Apers; Marloes Emous; Erik R E Totté; Bob Wilffert; Eric N van Roon
Journal:  Eur J Clin Pharmacol       Date:  2015-11-03       Impact factor: 2.953

Review 5.  An Evidence Map of the Women Veterans' Health Research Literature (2008-2015).

Authors:  Elisheva R Danan; Erin E Krebs; Kristine Ensrud; Eva Koeller; Roderick MacDonald; Tina Velasquez; Nancy Greer; Timothy J Wilt
Journal:  J Gen Intern Med       Date:  2017-09-14       Impact factor: 5.128

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.